Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
| ▸ | TEK | Q02763 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 5/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TGM1 | P22735 | 1/20 | 0.45 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21555674 | 0.80 | RAB9A (0.42) | LMNA | |
| SCHEMBL23089187 | 0.74 | HPGD (0.57) | LMNA | |
| SCHEMBL18285086 | 0.73 | NPC1 (0.61) | EGFRERBB2TEKKDRTGM2 | |
| SCHEMBL9952792 | 0.73 | CHRNB2 (0.52) | EGFRTEKKDRTGM2F13A1 | |
| SCHEMBL31357334 | 0.73 | CHRNB2 (0.52) | EGFRTEKKDRTGM2F13A1 | |
| SCHEMBL174072 | 0.73 | TGM2 (0.53) | EGFRTEKKDRTGM2LMNA | |
| SCHEMBL21808313 | 0.71 | TGM2 (0.49) | EGFRERBB2TEKKDRTGM2 | |
| SCHEMBL21566100 | 0.71 | GSK3B (0.40) | — | |
| SCHEMBL30075068 | 0.71 | GSK3B (0.40) | — | |
| SCHEMBL21808562 | 0.70 | TGM2 (0.43) | EGFRERBB2TEKKDRTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739695-B | Novel thiazole derivative and pharmaceutically acceptable salt thereof | 永进药品工业株式会社 | 2025-03-18 | — | — | CN | disclosed |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | YUNGJIN PHARM. CO., LTD. (KR) | 2024-10-08 | — | — | US | disclosed |
| EP-3853225-B1 | N-(5-(3-(1-((THIAZOL-2-YL)AMINO)-1-OXOPROPAN-2-YL)PHENYL)PYRIDIN-2-YL)ACRYLAMIDE DERIVATIVES AS CDK7 INHIBITORS FOR THE TREATMENT OF CANCER | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| US-20210284658-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | YUNGJIN PHARM. CO., LTD. (KR) | 2021-09-16 | — | — | US | disclosed |
| EP-3853225-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Yungjin Pharm. Co., Ltd. (KR) | 2021-07-28 | — | — | EP | disclosed |
| CN-112739695-A | Novel thiazole derivative and pharmaceutically acceptable salt thereof | 永进药品工业株式会社 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020060112-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | YUNGJIN PHARM. CO., LTD. (KR) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284658-A1 | NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CDKL1, CDKL3, CDKL2 | EGFR 1517/4885ERBB2 801/4885TEK 1263/4885 |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | CDKL1, CDK4, CDKL3 | EGFR 1533/4885ERBB2 745/4885TEK 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.